A randomized placebo-controlled trial of the effect of coffee consumption on insulin sensitivity: Design and baseline characteristics of the Coffee for METabolic Health (COMETH) study

Derrick Johnston Alperet, Salome Antonette Rebello, Eric Yin-Hao Khoo, Zoey Tay, Sharna Si-Ying Seah, Bee-Choo Tai, Shahram Emady-Azar, Chieh Jason Chou, Christian Darimont, Rob M van Dam, Derrick Johnston Alperet, Salome Antonette Rebello, Eric Yin-Hao Khoo, Zoey Tay, Sharna Si-Ying Seah, Bee-Choo Tai, Shahram Emady-Azar, Chieh Jason Chou, Christian Darimont, Rob M van Dam

Abstract

Background: Coffee consumption has been consistently associated with a lower risk of type 2 diabetes mellitus in cohort studies. In addition, coffee components increased insulin sensitivity in animal models. However, data from intervention studies on the effect of coffee consumption on glucose metabolism have been limited by small sample sizes, lack of blinding, short follow-up duration and the use of surrogate indices of insulin sensitivity. We designed the Coffee for Metabolic Health (COMETH) study to evaluate the effect of coffee consumption on insulin sensitivity.

Methodology: The COMETH study is a double-blind randomized placebo-controlled 24-week trial. Participants were overweight, male and female habitual coffee consumers who were of Chinese, Malay and Asian-Indian ethnicity. We excluded smokers, persons with diabetes, and persons with low insulin resistance (HOMA-IR < 1.30). Participants were randomly assigned to receive daily 4 cups of instant regular coffee or 4 cups of a coffee-like placebo beverage. The hyperinsulinemic euglycemic clamp was performed at baseline and at the end of 24 weeks to determine changes in the bodyweight standardized M-value. Secondary outcomes included changes in fasting glucose and insulin sensitivity mediators such as adiponectin, markers of inflammation, liver function, and oxidative stress.We enrolled 128 participants, 126 (57.1% males; aged 35-67 years) of whom completed baseline assessments.

Discussion: If improvement in insulin sensitivity in the coffee group is significantly greater than that of the placebo group, this would support the hypothesis that coffee consumption reduced risk of type 2 diabetes through biological pathways involving insulin sensitivity.

Trial registration: ClinicalTrials.gov identifier: NCT01738399. Registered on 28 November 2012. Trial Sponsor: Nestlé Research Center, Lausanne, Switzerland. Trial Site: National University of Singapore.

Keywords: Coffee; Hyperinsulinemic euglycemic clamp; Insulin resistance; Insulin sensitivity; Non-insulin dependent diabetes mellitus; Type 2 diabetes.

Figures

Fig. 1
Fig. 1
Timeline and activities of the Coffee for Metabolic Health (COMETH) study. Anthropometric measurements were performed at t = 0 min in all visits.
Fig. 2
Fig. 2
Trial profile of the Coffee for Metabolic Health (COMETH) study. *Screen failures were individuals who were found to be ineligible based on criteria such as high blood pressure and BMI, etc. These individuals were excluded without the need for a blood sample assessment.

References

    1. IDF Diabetes Atlas. sixth ed. International Diabetes Federation; 2013.
    1. Kahn S.E., Cooper M.E., Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383(9922):1068–1083.
    1. Ley S.H., Hamdy O., Mohan V., Hu F.B. Prevention and management of type 2 diabetes: dietary components and nutritional strategies. Lancet. 2014;383(9933):1999–2007.
    1. Global Coffee Trends: Finding the Premiumisation Opportunity. Euromonitor International; 2011.
    1. van Dam R.M., Feskens E.J. Coffee consumption and risk of type 2 diabetes mellitus. Lancet. 2002;360(9344):1477–1478.
    1. Ding M., Bhupathiraju S.N., Chen M., van Dam R.M., Hu F.B. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: a systematic review and a dose-response meta-analysis. Diabetes care. 2014;37(2):569–586.
    1. Kempf K., Herder C., Erlund I., Kolb H., Martin S., Carstensen M. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: a clinical trial. Am. J. Clin. Nutr. 2010;91(4):950–957.
    1. Wedick N.M., Brennan A.M., Sun Q., Hu F.B., Mantzoros C.S., van Dam R.M. Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial. Nutr. J. 2011;10:93.
    1. Ohnaka K., Ikeda M., Maki T., Okada T., Shimazoe T., Adachi M. Effects of 16-week consumption of caffeinated and decaffeinated instant coffee on glucose metabolism in a randomized controlled trial. J. Nutr. Metab. 2012;2012:207426.
    1. van Dam R.M., Pasman W.J., Verhoef P. Effects of coffee consumption on fasting blood glucose and insulin concentrations: randomized controlled trials in healthy volunteers. Diabetes care. 2004;27(12):2990–2992.
    1. Lecoultre V., Carrel G., Egli L., Binnert C., Boss A., MacMillan E.L. Coffee consumption attenuates short-term fructose-induced liver insulin resistance in healthy men. Am. J. Clin. Nutr. 2014;99(2):268–275.
    1. Singh B., Saxena A. Surrogate markers of insulin resistance: a review. World J. diabetes. 2010;1(2):36–47.
    1. The Singapore Consortium of Cohort Studies (SCCS). Singapore. . Accessed 21 July 2015.
    1. The Singapore Indian Eye Study 2 (SINDI–2) – Prospective cohort study of 6-year incidence, risk factors, and impact of retinal and other major eye diseases. Singapore Eye Research Institute. . Accessed 21 July 2015.
    1. Nang E.E., Khoo C.M., Tai E.S., Lim S.C., Tavintharan S., Wong T.Y. Is there a clear threshold for fasting plasma glucose that differentiates between those with and without neuropathy and chronic kidney disease?: the Singapore prospective study program. Am. J. Epidemiol. 2009;169(12):1454–1462.
    1. Katsuki A., Sumida Y., Gabazza E.C., Murashima S., Furuta M., Araki-Sasaki R. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes care. 2001;24(2):362–365.
    1. Pandis N. Randomization. Part 2: minimization. Am. J. Orthod. Dentofac. Orthop. Off. Publ. Am. Assoc. Orthod. its Const. Soc. Am. Board Orthod. 2011;140(6):902–904.
    1. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972;18(6):499–502.
    1. Deurenberg-Yap M., Li T., Tan W.L., van Staveren W.A., Deurenberg P. Validation of a semiquantitative food frequency questionnaire for estimation of intakes of energy, fats and cholesterol among Singaporeans. Asia Pac. J. Clin. Nutr. 2000;9(4):282–288.
    1. Report of the National Nutrition Survey. Health Promotion Board; Singapore: 2010. (Division RSP)
    1. Craig C.L., Marshall A.L., Sjostrom M., Bauman A.E., Booth M.L., Ainsworth B.E. International physical activity questionnaire: 12-country reliability and validity. Med. Sci. sports Exerc. 2003;35(8):1381–1395.
    1. International Physical Activity Questionnaire: Short Last 7 Days Self-administered Format for Use with Young and Middle-aged Adults (15-69 Years) The IPAQ Group; 2002.
    1. Schroevers M.J., Sanderman R., van Sonderen E., Ranchor A.V. The evaluation of the Center for Epidemiologic Studies Depression (CES-D) scale: depressed and positive affect in cancer patients and healthy reference subjects. Qual. life Res. Int. J. Qual. life aspects Treat. care Rehabil. 2000;9(9):1015–1029.
    1. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Appl. Psychol. Meas. 1977;1(3):385–401.
    1. Lai J.S., Cella D., Choi S., Junghaenel D.U., Christodoulou C., Gershon R. How item banks and their application can influence measurement practice in rehabilitation medicine: a PROMIS fatigue item bank example. Arch. Phys. Med. Rehabil. 2011;92(10 Suppl):S20–S27.
    1. Garcia S.F., Cella D., Clauser S.B., Flynn K.E., Lad T., Lai J.S. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007;25(32):5106–5112.
    1. Junghaenel D.U., Schneider S., Stone A.A., Christodoulou C., Broderick J.E. Ecological validity and clinical utility of Patient-reported outcomes measurement information system (PROMIS(R)) instruments for detecting premenstrual symptoms of depression, anger, and fatigue. J. Psychosom. Res. 2014;76(4):300–306.
    1. Broderick J.E., Schneider S., Junghaenel D.U., Schwartz J.E., Stone A.A. Validity and reliability of patient-reported outcomes measurement information system instruments in osteoarthritis. Arthritis care & Res. 2013;65(10):1625–1633.
    1. Markland A.D., Palsson O., Goode P.S., Burgio K.L., Busby-Whitehead J., Whitehead W.E. Association of low dietary intake of fiber and liquids with constipation: evidence from the National Health and Nutrition Examination Survey. Am. J. Gastroenterol. 2013;108(5):796–803.
    1. National Health and Nutrition Examination Survey Bowel Health Questionnaire (NHANES BHQ). . Accessed 15 May 2015.
    1. Francis C.Y., Morris J., Whorwell P.J. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Alimentary Pharmacol. Ther. 1997;11(2):395–402.
    1. DeFronzo R.A., Tobin J.D., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 1979;237(3):E214–E223.
    1. Muniyappa R., Lee S., Chen H., Quon M.J. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am. J. Physiol. Endocrinol. Metab. 2008;294(1):E15–E26.
    1. Brehm A., Roden M. Glucose clamp techniques. In: Roden M., editor. Clinical Diabetes Research: Methods and Techniques. John Wiley & Sons, Inc.; 2007. pp. 43–76.
    1. Tam C.S., Xie W., Johnson W.D., Cefalu W.T., Redman L.M., Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes care. 2012;35(7):1605–1610.
    1. Nerpin E., Riserus U., Ingelsson E., Sundstrom J., Jobs M., Larsson A. Insulin sensitivity measured with euglycemic clamp is independently associated with glomerular filtration rate in a community-based cohort. Diabetes care. 2008;31(8):1550–1555.
    1. Yuan T., Zhao W.G., Sun Q., Fu Y., Dong Y.Y., Dong Y.X. Association between four adipokines and insulin sensitivity in patients with obesity, type 1 or type 2 diabetes mellitus, and in the general Chinese population. Chin. Med. J. 2010;123(15):2018–2022.
    1. McAuley K.A., Williams S.M., Mann J.I., Goulding A., Chisholm A., Wilson N. Intensive lifestyle changes are necessary to improve insulin sensitivity: a randomized controlled trial. Diabetes care. 2002;25(3):445–452.
    1. Sun G., French C.R., Martin G.R., Younghusband B., Green R.C., Xie Y.G. Comparison of multifrequency bioelectrical impedance analysis with dual-energy X-ray absorptiometry for assessment of percentage body fat in a large, healthy population. Am. J. Clin. Nutr. 2005;81(1):74–78.
    1. Bergman R.N., Finegood D.T., Ader M. Assessment of insulin sensitivity in vivo. Endocr. Rev. 1985;6(1):45–86.
    1. Clifford M.N. Chlorogenic acids and other cinnamates – nature, occurrence and dietary burden. J. Sci. Food Agric. 1999;79(3):362–372. doi:10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>;2-D.
    1. Zhong B. How to calculate sample size in randomized controlled trial? J. Thorac. Dis. 2009;1(1):51–54.
    1. Schulz K.F., Altman D.G., Moher D. Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010;11:32.
    1. The Asia Pacific Perspective: Redefining Obesity and its Treatment. World Health Organization Western Pacific Region, International Association for the Study of Obesity & International Obesity Task Force; 2000.
    1. WHO . 2008. Waist Circumference and Waist-hip Ratio: Report of a WHO Expert Consultation. Geneva, Switzerland. 8–11 December 2008.
    1. Browning L.M., Hsieh S.D., Ashwell M. A systematic review of waist-to-height ratio as a screening tool for the prediction of cardiovascular disease and diabetes: 0.5 could be a suitable global boundary value. Nutr. Res. Rev. 2010;23(2):247–269.
    1. Deurenberg-Yap M., Chew S.K., Deurenberg P. Elevated body fat percentage and cardiovascular risks at low body mass index levels among Singaporean Chinese, Malays and Indians. Obes. Rev. Off. J. Int. Assoc. Study Obes. 2002;3(3):209–215.
    1. AST: MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine, National Institutes of Health; United States of America: 2013. Accessed 31 July 2014.
    1. ALT: MedlinePlus Medical Encyclopedia. U.S. National Library of Medicine, National Institutes of Health; United States of America: 2013. Accessed 31 July 2014.
    1. Conditions & Treatments: Cholesterol Management. SingHealth Group; Singapore: 2006. Accessed 31 July 2014.
    1. Nolan C.J., Damm P., Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378(9786):169–181.
    1. Matsuda M., DeFronzo R.A. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes care. 1999;22(9):1462–1470.
    1. Bokemark L., Froden A., Attvall S., Wikstrand J., Fagerberg B. The euglycemic hyperinsulinemic clamp examination: variability and reproducibility. Scand. J. Clin. Lab. Investig. 2000;60(1):27–36.
    1. Natella F., Scaccini C. Role of coffee in modulation of diabetes risk. Nutr. Rev. 2012;70(4):207–217.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi